Abstract
Phosphatidylinositol 3-kinase (PI3K), a heterodimeric lipid kinase, is a key enzyme in signal transduction from various stimuli to downstream pathways that elicit diverse responses involving growth, proliferation, survival, differentiation, and metabolism in many cellular systems. Activated PI3K generates phosphatidylinositol-3,4,5-triphosphate, which recruits phosphatidylinositol-dependent kinase 1 (PDK1) and Akt serine/threonine kinase at the plasma membrane, resulting in activation of Akt. In turn, Akt activates multiple downstream targets, most notably the mTOR pathway. There is abundant evidence implicating the PI3K/Akt/mTOR pathway in the development and progression of a variety of tumors including hematologic neoplasms. Therefore, this pathway is considered a critical target for cancer therapy. We review the regulatory mechanisms of the PI3K/Akt/mTOR signaling pathway and the role of this pathway in oncogenesis of hematological malignancies.
Keywords: PI3K, Akt, mTOR, hematologic malignancies
Anti-Cancer Agents in Medicinal Chemistry
Title: Regulation and Importance of the PI3K/Akt/mTOR Signaling Pathway in Hematologic Malignancies
Volume: 9 Issue: 9
Author(s): Kiyotaka Kawauchi, Toshie Ogasawara, Masako Yasuyama, Kuniaki Otsuka and Osamu Yamada
Affiliation:
Keywords: PI3K, Akt, mTOR, hematologic malignancies
Abstract: Phosphatidylinositol 3-kinase (PI3K), a heterodimeric lipid kinase, is a key enzyme in signal transduction from various stimuli to downstream pathways that elicit diverse responses involving growth, proliferation, survival, differentiation, and metabolism in many cellular systems. Activated PI3K generates phosphatidylinositol-3,4,5-triphosphate, which recruits phosphatidylinositol-dependent kinase 1 (PDK1) and Akt serine/threonine kinase at the plasma membrane, resulting in activation of Akt. In turn, Akt activates multiple downstream targets, most notably the mTOR pathway. There is abundant evidence implicating the PI3K/Akt/mTOR pathway in the development and progression of a variety of tumors including hematologic neoplasms. Therefore, this pathway is considered a critical target for cancer therapy. We review the regulatory mechanisms of the PI3K/Akt/mTOR signaling pathway and the role of this pathway in oncogenesis of hematological malignancies.
Export Options
About this article
Cite this article as:
Kawauchi Kiyotaka, Ogasawara Toshie, Yasuyama Masako, Otsuka Kuniaki and Yamada Osamu, Regulation and Importance of the PI3K/Akt/mTOR Signaling Pathway in Hematologic Malignancies, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (9) . https://dx.doi.org/10.2174/187152009789377772
DOI https://dx.doi.org/10.2174/187152009789377772 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Equipping CAR-Modified T Cells with a Brake to Prevent Chronic Adverse Effects
Current Gene Therapy Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry Anticancer Agents: Towards the Future
Current Medicinal Chemistry - Anti-Cancer Agents Cancer Invasion and Metastasis: Discovering New Targets For Diagnosis and Therapeutics
Current Signal Transduction Therapy Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews Gene Therapy for Primary Immunodeficiency Diseases: Recent Progress and Misgivings
Current Pharmaceutical Design Antiproliferative Effects of Nerium oleander Leaves and Their Cardiac Glycosides Odoroside A and Oleandrin on MCF-7 Cancer Cells
Current Traditional Medicine NK Cell Receptors and Their Interactions with MHC
Current Pharmaceutical Design Stabilization of Eukaryotic Topoisomerase II-DNA Cleavage Complexes
Current Topics in Medicinal Chemistry The Role of Micafungin and Anidulafungin in the Treatment of Systemic Fungal Infections: Applications and Patents for Two Novel Echinocandins
Recent Patents on Anti-Infective Drug Discovery Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia
Current Drug Targets Altered Expression of MicroRNAs in the Bone Marrow of Multiple Myeloma Patients and their Relationship to Cytogenetic Aberrations
Current Pharmaceutical Biotechnology Antithrombotic Treatment in the Prevention of Ischemic Stroke
Current Drug Targets Advances in Biologic Agents for the Treatment of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma
Current Pharmaceutical Biotechnology RNA Interference-Mediated Validation of Survivin and Apollon/BRUCE as New Therapeutic Targets for Cancer Therapy
Current Topics in Medicinal Chemistry Angiogenesis and Anti-angiogenic Therapies in Epithelial Ovarian Cancer
Current Angiogenesis (Discontinued) Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets